- Home
- NXPI vs TAK Comparison
NXPI vs TAK Comparison
Compare NXPI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPI | TAK |
|---|---|---|
| Founded | 2006 | 1781 |
| Country | Netherlands | Japan |
| Employees | N/A | 47455 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9B | 52.4B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | NXPI | TAK |
|---|---|---|
| Price | $323.13 | $15.96 |
| Analyst Decision | Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $285.76 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 3.1M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | 1.40% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.43 | N/A |
| Revenue | ★ $12,269,000,000.00 | N/A |
| Revenue This Year | $12.56 | $0.16 |
| Revenue Next Year | $10.17 | $1.22 |
| P/E Ratio | $74.75 | ★ $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $183.00 | $12.99 |
| 52 Week High | $339.95 | $18.90 |
Technical Indicators
Market Signals| Indicator | NXPI | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 66.89 | 34.14 |
| Support Level | $211.84 | $15.88 |
| Resistance Level | N/A | $16.48 |
| Average True Range (ATR) | 12.95 | 0.23 |
| MACD | 0.35 | -0.01 |
| Stochastic Oscillator | 70.13 | 14.67 |
Price Performance
Historical ComparisonAbout NXPI NXP Semiconductors N.V.
NXP Semiconductors is a leading supplier of high-performance mixed-signal products. The firm acquired Freescale Semiconductor in 2015 and now has significant market share in the automotive market, where it supplies microcontrollers and analog chips into automotive clusters, powertrains, infotainment systems, and radars. NXP Semiconductors also serves industrial and Internet of Things, mobile, and communications infrastructure.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.